One-year mortality after implantable defibrillator implantation: do risk stratification models help improving clinical practice?

[1]  C. Israel,et al.  2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[3]  P. Austin,et al.  MACHINE LEARNING COMPARED TO CONVENTIONAL STATISTICAL MODELS FOR PREDICTING MYOCARDIAL INFARCTION READMISSION AND MORTALITY: A SYSTEMATIC REVIEW. , 2021, The Canadian journal of cardiology.

[4]  W. Zareba,et al.  Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. , 2021, European heart journal.

[5]  P. Austin,et al.  Machine learning vs. conventional statistical models for predicting heart failure readmission and mortality , 2020, ESC heart failure.

[6]  M. Kamalesh,et al.  One‐year mortality after implantable cardioverter‐defibrillator placement within the Veterans Affairs Health System , 2020, European journal of heart failure.

[7]  B. Merkely,et al.  Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score , 2020, European heart journal.

[8]  P. Della Bella,et al.  Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: A survey from the Home Monitoring Expert Alliance project , 2018, Clinical cardiology.

[9]  S. Rosenheck,et al.  Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry , 2018, Journal of cardiovascular electrophysiology.

[10]  G. Hindricks,et al.  CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? , 2018, European journal of heart failure.

[11]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[12]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[13]  S. Saba,et al.  Usefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients. , 2017, The American journal of cardiology.

[14]  M. Rosenqvist,et al.  Clinical risk profile score predicts all cause mortality but not implantable cardioverter defibrillator intervention rate in a large unselected cohort of patients with congestive heart failure , 2017, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[15]  G. Gislason,et al.  The impact of co‐morbidity burden on appropriate implantable cardioverter defibrillator therapy and all‐cause mortality: insight from Danish nationwide clinical registers , 2017, European journal of heart failure.

[16]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[17]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[18]  M. Turakhia,et al.  A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. , 2015, American heart journal.

[19]  G. Hindricks,et al.  Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial , 2014, The Lancet.

[20]  Lluís Mont,et al.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  Jeroen J. Bax,et al.  Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score , 2012, Heart.

[22]  L. Jordaens,et al.  Pre-implantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[23]  L. Jordaens,et al.  The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[24]  A. Moss,et al.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. , 2008, Journal of the American College of Cardiology.

[25]  Peter C Austin,et al.  Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. , 2007, Journal of the American College of Cardiology.

[26]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[27]  W. Stevenson,et al.  Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. , 2006, American heart journal.

[28]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[29]  J. Nielsen,et al.  ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .

[30]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[31]  D. Hodge,et al.  Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. , 2012, Heart rhythm.

[32]  Yulei He,et al.  Missing data analysis using multiple imputation: getting to the heart of the matter. , 2010, Circulation. Cardiovascular quality and outcomes.

[33]  A. Hallstrom,et al.  Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable d , 2001, American heart journal.